Vensica Medical Secures $11M in Funding to Support Phase 2 Trials for Overactive Bladder Treatment
Rhea-AI Summary
Vensica Medical has secured an $11 million funding round led by Israel Biotech Fund (IBF), with participation from strategic partners Merz and Laborie. The funding will support Phase 2 clinical trials in the US and Europe for their innovative overactive bladder (OAB) treatment. The company's proprietary technology delivers botulinum toxin A (Xeomin®) through a needle-free device directly to the bladder wall, offering a potentially less invasive alternative to traditional injections. Through its partnership with Merz, Vensica has obtained exclusive rights to Xeomin® for needle-less applications in various urologic indications.
Positive
- Secured $11 million in new funding
- Strategic partnerships with established companies Merz and Laborie
- Exclusive rights to Xeomin® for needle-less urologic applications
- Advancing to Phase 2 clinical trials in US and Europe
Negative
- Product still in clinical trial phase, not yet commercialized
- Requires successful completion of Phase 2 trials before potential market entry
Backed by IBF, Merz, and Laborie, Vensica to Advance Needle-Free Delivery of Botulinum Toxin A (Xeomin®) for Minimally Invasive Treatment
The investment round was led by Israel Biotech Fund (IBF), alongside key strategic partners, Merz, a global player in neurotoxins, and Laborie, a prominent urology medical device company. This funding will enable Vensica to continue its mission of providing a minimally invasive, simple, and effective solution for people with overactive bladder ("OAB").
Vensica's unique technology leverages a needle-free drug delivery system, that administers Xeomin® directly to the bladder wall. This approach is expected to offer patients a less invasive, more comfortable treatment option compared to traditional injections, potentially transforming the standard of care for OAB. Vensica's needle-free drug delivery system aims to be a urology treatment platform for the treatment of additional bladder indications.
"We are thrilled to have the support of leading investors and partners who share our vision of transforming overactive bladder treatment," remarked Avner Geva, CEO of Vensica. "This funding will allow us to push forward with Phase 2 trials and move one step closer to bringing this innovative therapy to the patients who need it."
As part of its strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic application in several urologic indications and will benefit from Merz's clinical development support. This collaboration marks a significant step forward in the company's goal of delivering next-generation urology treatments.
For more information on Vensica and its upcoming clinical trials, visit https://vensica.com/.
About Vensica Medical
Vensica Medical is a biotechnology company focused on developing novel therapies for urological conditions. The company's leading product is a needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder in a minimally invasive manner. Vensica was established in the incubator program of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.
Contact:
Avner Geva, Chief Executive Officer
avner@vensica.com
Photo: https://mma.prnewswire.com/media/2541677/CTO_Co_Founder_Vensica_Medical.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder-treatment-302288449.html
SOURCE Vensica Medical
FAQ
What is the size of Vensica Medical's latest funding round?
What is Vensica Medical's new treatment method for overactive bladder?
What phase of clinical trials is Vensica Medical entering for their OAB treatment?
What exclusive rights has Vensica Medical secured from Merz?
